GlaxoSmithKline Pharmaceuticals Ltd banner

GlaxoSmithKline Pharmaceuticals Ltd
NSE:GLAXO

Watchlist Manager
GlaxoSmithKline Pharmaceuticals Ltd Logo
GlaxoSmithKline Pharmaceuticals Ltd
NSE:GLAXO
Watchlist
Price: 2 336.4 INR -1.28% Market Closed
Market Cap: ₹395.8B

P/FCFE

58.9
Current
15%
More Expensive
vs 3-y average of 51.2

Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.

P/FCFE
58.9
=
Market Cap
₹448.6B
/
Free Cash Flow to Equity
₹6.7B

Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.

P/FCFE
58.9
=
Market Cap
₹448.6B
/
Free Cash Flow to Equity
₹6.7B

Valuation Scenarios

GlaxoSmithKline Pharmaceuticals Ltd is trading above its 3-year average

If P/FCFE returns to its 3-Year Average (51.2), the stock would be worth ₹2 030.49 (13% downside from current price).

Statistics
Positive Scenarios
0/4
Maximum Downside
-21%
Maximum Upside
No Upside Scenarios
Average Downside
13%
Scenario P/FCFE Value Implied Price Upside/Downside
Current Multiple 58.9 ₹2 336.4
0%
3-Year Average 51.2 ₹2 030.49
-13%
5-Year Average 46.5 ₹1 843.74
-21%
Industry Average 57.9 ₹2 298.39
-2%
Country Average 49.7 ₹1 973.93
-16%

Forward P/FCFE
Today’s price vs future free cash flow to equity

Not enough data available to calculate forward P/FCFE

Peer Comparison

All Multiples
P/FCFE
P/E
All Countries
Close
Market Cap P/FCFE P/E
IN
GlaxoSmithKline Pharmaceuticals Ltd
NSE:GLAXO
395.8B INR 58.9 38.8
US
Eli Lilly and Co
NYSE:LLY
908.9B USD 61.3 36
US
Johnson & Johnson
NYSE:JNJ
547.1B USD 21 26
CH
Roche Holding AG
SIX:ROG
248.4B CHF 27.5 20.1
UK
AstraZeneca PLC
LSE:AZN
209.6B GBP 36.2 27.4
CH
Novartis AG
SIX:NOVN
221.1B CHF 9.4 20.7
US
Merck & Co Inc
NYSE:MRK
277.6B USD 12.2 31.1
IE
Endo International PLC
LSE:0Y5F
244.4B USD -766.6 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 24.3 12.1
US
Pfizer Inc
NYSE:PFE
149.7B USD 24.3 19.3
US
Bristol-Myers Squibb Co
NYSE:BMY
118.9B USD 37.8 4 516.9
P/E Multiple
Earnings Growth PEG
IN
GlaxoSmithKline Pharmaceuticals Ltd
NSE:GLAXO
Average P/E: 474.8
38.8
14%
2.8
US
Eli Lilly and Co
NYSE:LLY
36
32%
1.1
US
Johnson & Johnson
NYSE:JNJ
26
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
27.4
25%
1.1
CH
Novartis AG
SIX:NOVN
20.7
14%
1.5
US
Merck & Co Inc
NYSE:MRK
31.1
14%
2.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
12.1
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.3
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
4 516.9
648%
7

Market Distribution

In line with most companies in India
Percentile
56th
Based on 1 683 companies
56th percentile
58.9
Low
0.6 — 27.4
Typical Range
27.4 — 92
High
92 —
Distribution Statistics
India
Min 0.6
30th Percentile 27.4
Median 49.7
70th Percentile 92
Max 57 010.1

GlaxoSmithKline Pharmaceuticals Ltd
Glance View

Market Cap
395.8B INR
Industry
Pharmaceuticals

GlaxoSmithKline Pharmaceuticals Ltd., a subsidiary of the global healthcare juggernaut GSK, stands as a pillar in the pharmaceutical industry, with roots deeply entrenched in innovation and a robust pipeline of healthcare products. This company weaves a narrative of relentless pursuit in the creation and distribution of a wide variety of medicines and vaccines, aimed at improving the quality of human life. Operating predominantly in the areas of pharmaceuticals, vaccines, and consumer healthcare, GSK integrates cutting-edge research with strategic collaborations. This enables them to address pressing medical needs, such as respiratory diseases, HIV, infectious diseases, and oncology, amongst others, thereby leveraging their expertise to cater to diverse healthcare demands. The heart of their revenue generation lies in the seamless amalgamation of research acumen and market presence. By investing significantly in research and development, GSK continually introduces groundbreaking therapies and health solutions. The company has adeptly structured its operations to create a strong global presence, which not only involves selling directly to healthcare providers and governments but also innovating its supply chain to maximize reach. Moreover, GSK's astute marketing efforts ensure that their products are not just effective but also attuned to consumer needs. With a focus on sustainable growth and transformative medicines, GSK’s story becomes a testament to how science-driven strategies can forge pathways to a healthier world while simultaneously fueling the company’s economic engine.

GLAXO Intrinsic Value
1 376.65 INR
Overvaluation 41%
Intrinsic Value
Price ₹2 336.4
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett